ZA952206B - Scintigraphic imaging agents - Google Patents

Scintigraphic imaging agents

Info

Publication number
ZA952206B
ZA952206B ZA952206A ZA952206A ZA952206B ZA 952206 B ZA952206 B ZA 952206B ZA 952206 A ZA952206 A ZA 952206A ZA 952206 A ZA952206 A ZA 952206A ZA 952206 B ZA952206 B ZA 952206B
Authority
ZA
South Africa
Prior art keywords
imaging agents
scintigraphic imaging
reagents
agents
radiolabeled compounds
Prior art date
Application number
ZA952206A
Other languages
English (en)
Inventor
John Lister-James
Original Assignee
Diatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Inc filed Critical Diatech Inc
Publication of ZA952206B publication Critical patent/ZA952206B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA952206A 1994-03-18 1995-03-17 Scintigraphic imaging agents ZA952206B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21082294A 1994-03-18 1994-03-18

Publications (1)

Publication Number Publication Date
ZA952206B true ZA952206B (en) 1995-12-12

Family

ID=22784384

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952206A ZA952206B (en) 1994-03-18 1995-03-17 Scintigraphic imaging agents

Country Status (8)

Country Link
EP (1) EP0750610B1 (de)
AT (1) ATE210644T1 (de)
AU (1) AU2186695A (de)
DE (1) DE69524580T2 (de)
DK (1) DK0750610T3 (de)
ES (1) ES2169756T3 (de)
WO (1) WO1995025720A1 (de)
ZA (1) ZA952206B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
JP2774378B2 (ja) * 1991-02-08 1998-07-09 ダイアテク,インコーポレイテッド 映像用テクネチウム−99m標識化ポリペプチド
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5508020A (en) * 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
DE69334033D1 (de) * 1992-05-21 2006-07-27 Diatide Inc Technetium-99M markierte Peptide zur Bilderzeugung von Thrombus

Also Published As

Publication number Publication date
DE69524580D1 (de) 2002-01-24
ATE210644T1 (de) 2001-12-15
ES2169756T3 (es) 2002-07-16
WO1995025720A1 (en) 1995-09-28
DE69524580T2 (de) 2002-07-25
EP0750610A1 (de) 1997-01-02
EP0750610B1 (de) 2001-12-12
AU2186695A (en) 1995-10-09
DK0750610T3 (da) 2002-03-11

Similar Documents

Publication Publication Date Title
DK0641222T3 (da) Peptider mærket med technetium-99m til trombeafbildning
DE69326335D1 (de) Technetium-99M-markierte peptide zur Bilderzeugung
DK0693941T3 (da) Radiomærkede forbindelser til trombe-billeddannelse
LV11106A (lv) Radioiezimeti trombocitu GPIIb/IIIa receptora antagonisti ka attelu veidojoss lidzeklis
AU3602795A (en) Tc or re radiolabelled somatostatin analogs
DK0644778T3 (da) Technetium-99-mærkede peptider til imagografi
WO1993010747A3 (en) Technetium-99m labeled peptides for imaging
AU7366687A (en) Coupling agents for radiolabeling proteins
GR3032851T3 (en) TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING.
DK0630265T3 (da) Technetium-99m mærkede peptider til afbildning af inflammation
ATE67679T1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
CA2191951A1 (en) Monoamine, diamide, thiol-containing metal chelating agents
DK0649434T3 (da) Radioaktivt mærkede somatostatin-afledte peptider til billeddannende og terapeutiske anvendelser
DK0684843T3 (da) Technetium-99m-mærkede peptider til diagnostisk billeddannelse af inflammation
ZA954547B (en) Technetium-99m labeled peptides for imaging
ATE234639T1 (de) Technetium-99m markierte bildformungsmittel
AU2186695A (en) Piperidyl-4-substituted thyrosine derivatives as scintigraphic imaging agents for the diagnosis of thrombosis
BR9809785A (pt) Composto de ligação de receptor de calcitonina, reagente, agente de formação de imagem cintigráfica, composição, agente radio-terapêutico, complexo, kit para preparar uma preparação radio-farmacêutica, processos para rotular o reagente, para fabricar o reagente, e, uso do reagente
ATE258176T1 (de) Neue azabicyclo derivate und ihre verwendung
WO1995025720B1 (en) Piperidyl-4-substituted thyrosine derivatives as scintigraphic imaging agents for the diagnosis of thrombosis
DE69426035D1 (de) Radiomarkierte glukane
CA2031528A1 (en) Radionuclide metal chelates for the radiolabeling of proteins
KR900003171A (ko) 방사성요오드화 벤조디아제핀 유도체
EP0498333A3 (en) Preparation of an organospecific substance marked with technetium-99m